跳转到主内容

非常抱歉,我们不完全支持您的浏览器。如果您可以选择,请升级到较新版本或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更高版本。如果您无法进行此操作且需要支持,请将您的反馈发送给我们。

全新设计的官网为您带来全新体验,期待您的反馈在新的选项卡/窗口中打开

Elsevier
通过我们出版
ClinicalPath patient
Whitepaper

The prior authorization bottleneck is costing patients time they don’t have

Prior authorization in oncology shouldn’t force a tradeoff between oversight and timely patient care. Yet today’s manual, fragmented processes often delay decisions, burden clinicians and staff, and leave patients waiting when time matters most.

There is a better way forward.

In this white paper from ClinicalPath, leaders from provider organizations and health plans—alongside oncology pathway experts—explore how evidence-based pathways can power automated prior authorization. The result: faster decisions, fewer administrative barriers, and uncompromised clinical rigor.

What you’ll learn:

  • How to seamlessly embed pathways within EHR workflows

  • How standards-based data exchange enables faster approvals for guideline-concordant care

  • Which structured data elements (stage, biomarkers, intent, line of therapy) streamline review processes

  • How enhanced reporting drives transparency, supports gold-carding, and aligns with value-based care goals

  • What’s next: fast-lane models, bundled authorizations, and responsible AI to accelerate approvals

Discover a clear, actionable roadmap to transform oncology prior authorization.

Download the white paper to learn how pathway-driven care can reduce friction across stakeholders and help ensure patients receive timely, guideline-concordant treatment.

The prior authorization bottleneck white paper cover image

The prior authorization bottleneck is costing patients time they don’t have

Download the white paper 在新的选项卡/窗口中打开